Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial
Open Access
- 2 April 2009
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 7 (1), 13
- https://doi.org/10.1186/1741-7015-7-13
Abstract
Background Intradermal vaccination provides direct and potentially more efficient access to the immune system via specialised dendritic cells and draining lymphatic vessels. We investigated the immunogenicity and safety during 3 successive years of different dosages of a trivalent, inactivated, split-virion vaccine against seasonal influenza given intradermally using a microinjection system compared with an intramuscular control vaccine. Methods In a randomised, partially blinded, controlled study, healthy volunteers (1150 aged 18 to 57 years at enrolment) received three annual vaccinations of intradermal or intramuscular vaccine. In Year 1, subjects were randomised to one of three groups: 3 μg or 6 μg haemagglutinin/strain/dose of inactivated influenza vaccine intradermally, or a licensed inactivated influenza vaccine intramuscularly containing 15 μg/strain/dose. In Year 2 subjects were randomised again to one of two groups: 9 μg/strain/dose intradermally or 15 μg intramuscularly. In Year 3 subjects were randomised a third time to one of two groups: 9 μg intradermally or 15 μg intramuscularly. Randomisation lists in Year 1 were stratified for site. Randomisation lists in Years 2 and 3 were stratified for site and by vaccine received in previous years to ensure the inclusion of a comparable number of subjects in a vaccine group at each centre each year. Immunogenicity was assessed 21 days after each vaccination. Safety was assessed throughout the study. Results In Years 2 and 3, 9 μg intradermal was comparably immunogenic to 15 μg intramuscular for all strains, and both vaccines met European requirements for annual licensing of influenza vaccines. The 3 μg and 6 μg intradermal formulations were less immunogenic than intramuscular 15 μg. Safety of the intradermal and intramuscular vaccinations was comparable in each year of the study. Injection site erythema and swelling was more common with the intradermal route. Conclusion An influenza vaccine with 9 μg of haemagglutinin/strain given using an intradermal microinjection system showed comparable immunogenic and safety profiles to a licensed intramuscular vaccine, and presents a promising alternative to intramuscular vaccination for influenza for adults younger than 60 years. Trial registration Clinicaltrials.gov NCT00703651.Keywords
This publication has 39 references indexed in Scilit:
- Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practiceExpert Review of Vaccines, 2008
- Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled TrialThe Journal of Infectious Diseases, 2008
- Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasonsBMC Public Health, 2008
- Non-Traditional Settings for Influenza Vaccination of AdultsPharmacoEconomics, 2008
- Lessons from 40 years' surveillance of influenza in England and WalesEpidemiology and Infection, 2007
- Influenza Vaccination Coverage Rates in 5 European Countries: a Population-Based Cross-Sectional Analysis of the Seasons 02/03, 03/04 and 04/05Infection, 2007
- Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adultsVaccine, 2007
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Pharmacoeconomics of Influenza Vaccination for Healthy Working AdultsDrugs, 2002
- Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trialTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999